Results 131 to 140 of about 926 (182)

PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. [PDF]

Hepatol Commun
Hayes CM, Gallucci GM, Boyer JL, Assis DN, Ghonem NS.   +4 more
europepmc   +1 more source

Liver Organoids From Hepatocytes of Healthy Humans and Non-alcoholic Fatty Liver Disease (NAFLD) Patients Display Multilineage Architecture and can be Used to Develop an <i>In Vitro</i> Model of Steatohepatitis. [PDF]

J Clin Exp Hepatol
Goswami Y, Baghel A, Sharma G, Sharma PK, Biswas S, Yadav R, Garg PK, Shalimar, Tandon R.   +8 more
europepmc   +1 more source

Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities. [PDF]

Biomedicines
Prikhodko VA, Okovityi SV.
europepmc   +1 more source

Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis. [PDF]

Ther Adv Gastroenterol
Liao W, Fu S, Yang A, Yang Y.
europepmc   +1 more source

The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives. [PDF]

J Pers Med
Romeo M, Di Nardo F, Basile C, Napolitano C, Vaia P, Martinelli G, Gregorio A, Puorto LD, Indipendente M, Dallio M, Federico A.   +10 more
europepmc   +1 more source

Selective PPARα Modulator (SPPARMα) in the Era of the MASLD Pandemic: Current Insights and Future Prospects. [PDF]

Yonago Acta Med
Sugihara T.
europepmc   +1 more source

Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Attia SH, Saadawy SF, El-Mahroky SM, Nageeb MM.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020
Saroglitazar is commonly used in India for managing hypertriglyceridemia in diabetes. This meta-analysis evaluated the efficacy and safety of saroglitazar in hypertriglyceridemia.Electronic databases were searched for RCTs involving diabetes patients receiving saroglitazar in intervention arm, and placebo/lipid/diabetes medication in the control arm ...
Deep Dutta, Saptarshi Bhattacharya, Sameer Aggarwal   +2 more
exaly   +3 more sources